Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt.
J Nanobiotechnology. 2019 Jan 19;17(1):7. doi: 10.1186/s12951-019-0445-7.
The rationale of this study is to combine the merits of both albumin nanoparticles and quantum dots (QDs) in improved drug tumor accumulation and strong fluorescence imaging capability into one carrier. However, premature drug release from protein nanoparticles and high toxicity of QDs due to heavy metal leakage are among challenging hurdles. Following this platform, we developed cancer nano-theranostics by coupling biocompatible albumin backbone to CdTe QDs and mannose moieties to enhance tumor targeting and reduce QDs toxicity. The chemotherapeutic water soluble drug pemetrexed (PMT) was conjugated via tumor-cleavable bond to the albumin backbone for tumor site-specific release. In combination, the herbal hydrophobic drug resveratrol (RSV) was preformulated as phospholipid complex which enabled its physical encapsulation into albumin nanoparticles.
Albumin-QDs theranostics showed enhanced cytotoxicity and internalization into breast cancer cells that could be traced by virtue of their high fluorescence quantum yield and excellent imaging capacity. In vivo, the nanocarriers demonstrated superior anti-tumor effects including reduced tumor volume, increased apoptosis, and inhibited angiogenesis in addition to non-immunogenic response. Moreover, in vivo bioimaging test demonstrated excellent tumor-specific accumulation of targeted nanocarriers via QDs-mediated fluorescence.
Mannose-grafted strategy and QD-fluorescence capability were beneficial to deliver albumin nanocarriers to tumor tissues and then to release the anticancer drugs for killing cancer cells as well as enabling tumor imaging facility. Overall, we believe albumin-QDs nanoplatform could be a potential nano-theranostic for bioimaging and targeted breast cancer therapy.
本研究的原理是将白蛋白纳米粒子和量子点(QDs)的优点结合到一个载体中,以提高药物在肿瘤中的积累和强大的荧光成像能力。然而,由于重金属泄漏,蛋白质纳米粒子过早释放药物和 QDs 的高毒性是具有挑战性的障碍。在这个平台上,我们通过将生物相容性的白蛋白主链与 CdTe QDs 和甘露糖部分偶联,增强肿瘤靶向性并降低 QDs 的毒性,开发了癌症纳米治疗。化疗水溶性药物培美曲塞(PMT)通过肿瘤可裂解键与白蛋白主链偶联,实现肿瘤部位的特异性释放。此外,将疏水性草药药物白藜芦醇(RSV)预先制成磷脂复合物,使其能够物理包封到白蛋白纳米粒子中。
白蛋白-QDs 治疗剂显示出增强的细胞毒性和进入乳腺癌细胞的内化能力,这得益于其高荧光量子产率和出色的成像能力。在体内,纳米载体表现出优异的抗肿瘤效果,包括减少肿瘤体积、增加细胞凋亡和抑制血管生成,同时还具有非免疫原性反应。此外,体内生物成像测试表明,通过 QD 介导的荧光,靶向纳米载体具有优异的肿瘤特异性积累。
甘露糖接枝策略和 QD 荧光能力有利于将白蛋白纳米载体递送到肿瘤组织中,然后释放抗癌药物以杀死癌细胞,并实现肿瘤成像功能。总的来说,我们相信白蛋白-QDs 纳米平台可以成为生物成像和靶向乳腺癌治疗的潜在纳米治疗剂。